 Connection
Erin Schenk to Immunotherapy
This is a "connection" page, showing publications Erin Schenk has written about Immunotherapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.321 |
|
|
|
-
Schenk EL, Patil T, Pacheco J, Bunn PA. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2021 03; 26(3):e454-e472.
Score: 0.114
-
Camidge DR, Schenk EL. Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer. Cell. 2020 10 15; 183(2):303-304.
Score: 0.113
-
Florez N, Patel SP, Salgia R, Sands J, Schenk EL, Shum E, Aldea M, Bestvina CM, Donington J, Garcia CA, Nieva J, Gandara DR, Halmos B, Hirsch FR, Le X, Lee P, Malhotra J, Patil T, Peters S, Riess JW, Rotow J, Rous FA, Sabari J, Sen T, Singhi EK, Velázquez AI, Wakelee HA, Kim ES. Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025. Cancer. 2026 Oct 01; 132(19):e70633.
Score: 0.043
-
Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Front Immunol. 2019; 10:954.
Score: 0.026
-
Bunn PA, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology (Williston Park). 2019 Mar 13; 33(3):101-6, 109.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|